hydroxyurea has been researched along with Cerebrovascular Disorders in 9 studies
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| "Hydroxyurea has proven efficacy in numerous clinical trials as a disease-modifying treatment for patients with sickle cell anemia (SCA) but is currently under-used in clinical practice." | 1.42 | Optimizing hydroxyurea therapy for sickle cell anemia. ( Ware, RE, 2015) |
| "Stroke is a common cause of morbidity and mortality in sickle cell disease (SCD) and silent cerebral infarction is the most common form of neurologic injury." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
| "Hydroxyurea can increase fetal hemoglobin (HbF) and improve the clinical course of sickle cell disease (SCD) patients." | 1.29 | A cautionary note regarding hydroxyurea in sickle cell disease. ( Lubin, BH; Vichinsky, EP, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Bernaudin, F | 1 |
| Rankine-Mullings, A | 1 |
| Reid, M | 1 |
| Soares, D | 1 |
| Taylor-Bryan, C | 1 |
| Wisdom-Phipps, M | 1 |
| Aldred, K | 1 |
| Latham, T | 1 |
| Schultz, WH | 1 |
| Knight-Madden, J | 1 |
| Badaloo, A | 1 |
| Lane, A | 1 |
| Adams, RJ | 1 |
| Ware, RE | 4 |
| Ansari, J | 1 |
| Moufarrej, YE | 1 |
| Pawlinski, R | 1 |
| Gavins, FNE | 1 |
| Rigano, P | 1 |
| Pecoraro, A | 1 |
| Calvaruso, G | 1 |
| Steinberg, MH | 2 |
| Iannello, S | 1 |
| Maggio, A | 1 |
| de Montalembert, M | 2 |
| Tshilolo, L | 1 |
| Abboud, MR | 1 |
| Brousse, V | 1 |
| Gandhi, S | 1 |
| Height, S | 1 |
| Dick, MC | 1 |
| O'Driscoll, S | 1 |
| Abihsera, G | 1 |
| Rees, DC | 1 |
| Vichinsky, EP | 1 |
| Lubin, BH | 1 |
| Kinney, TR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxyurea and Cerebrovascular Disorders
| Article | Year |
|---|---|
What is the place of hematopoietic stem cell transplantation in the management of cerebral vasculopathy in children with sickle cell anemia?
Topics: Allografts; Anemia, Sickle Cell; Cerebrovascular Disorders; Child; Hematopoietic Stem Cell Transplan | 2020 |
Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Communication; Cerebrovascular Disorders; Disease Pro | 2018 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
1 trial available for hydroxyurea and Cerebrovascular Disorders
| Article | Year |
|---|---|
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Flow Velocity; Cerebrovascular Circulati | 2021 |
5 other studies available for hydroxyurea and Cerebrovascular Disorders
| Article | Year |
|---|---|
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Optimizing hydroxyurea therapy for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Drug Adminis | 2015 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |
A cautionary note regarding hydroxyurea in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal | 1994 |
Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Blood Group Incompatibility; Blood Transfusion; Cerebrovascular Disorder | 1995 |